Summary & Overview
CPT 77763: Intracavitary Brachytherapy with Multiple Source Implants
CPT code 77763 designates intracavitary brachytherapy in which more than 10 radioactive sources are placed inside a body cavity to treat malignancy. This procedure enables concentrated radiation delivery directly to a tumor site while limiting exposure to surrounding tissues, making it clinically important for cancers such as prostate and select gynecologic or thoracic tumors. Nationally, the code matters for surgical oncology practices, radiation oncology departments, and payers managing high-cost specialty procedures.
Key payers relevant to coverage and payment discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context and typical settings for the service, plus coverage and reimbursement benchmarks where available. The publication summarizes national payment considerations, common billing modifiers encountered with the code, and how the procedure maps to radiation oncology service lines. It also highlights coding relationships and areas where administrators and coders should confirm documentation for implant counts and intracavitary technique.
The analysis is intended for hospital billing teams, radiation oncologists, and revenue cycle managers seeking a national overview of clinical use, billing context, and payer engagement for CPT code 77763.
Billing Code Overview
CPT code 77763 describes a brachytherapy procedure in which the provider places more than 10 radioactive sources (implants) inside a body cavity to deliver localized radiation therapy. The intent of the procedure is cancer treatment by positioning radioactive implants in or adjacent to a tumor; prostate cancer is a common indication for this technique.
-
Service type: High-dose or multi-source intracavitary brachytherapy procedure
-
Typical site of service: Ambulatory surgical center or hospital operating room; procedures are performed in or near body cavities such as the prostate, vagina, or thoracic cavity depending on the tumor location.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old man with intermediate- to high-risk localized prostate adenocarcinoma who is evaluated by a multidisciplinary team including a radiation oncologist and urologist. After staging with prostate biopsy, prostate-specific antigen (PSA) trends, and pelvic MRI showing a lesion confined to the prostate with no distant metastasis, the team elects for brachytherapy using permanent or temporary radioactive source implants. The patient is seen in the outpatient radiation oncology clinic for pre-procedure education and consent, then scheduled for the procedure in an ambulatory surgery center or hospital operating room under monitored anesthesia care or general anesthesia.
On the day of service the patient undergoes transperineal ultrasound-guided placement of more than 10 radioactive seeds or catheters into the prostate using a transrectal ultrasound template or stereotactic guidance. Intraoperative dosimetry verifies seed placement and target coverage. Post-implant imaging (CT or MRI) is obtained the same day or within 30 days to document implant geometry and dosimetry. Typical follow-up includes short-term assessment for urinary retention, hematuria, or rectal irritation, and serial PSA monitoring at regular intervals. The procedure is performed in settings such as hospital-based operating rooms, ambulatory surgery centers, or specialized radiation oncology suites equipped for brachytherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |